4D Molecular Therapeutics (NASDAQ:FDMT) Stock Price Down 3.7% – Here’s What Happened

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) shares were down 3.7% on Friday . The company traded as low as $15.48 and last traded at $15.50. Approximately 533,967 shares changed hands during trading, a decline of 35% from the average session volume of 825,387 shares. The stock had previously closed at $16.10.

Analyst Ratings Changes

A number of brokerages have issued reports on FDMT. The Goldman Sachs Group reiterated a “buy” rating and issued a $32.00 price target on shares of 4D Molecular Therapeutics in a research note on Thursday, August 13th. B. Riley Financial reaffirmed a “buy” rating on shares of 4D Molecular Therapeutics in a research note on Monday, August 17th. HC Wainwright reissued a “buy” rating and set a $36.00 target price on shares of 4D Molecular Therapeutics in a research note on Monday, July 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a report on Friday, July 17th. Finally, Wall Street Zen cut shares of 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $29.62.

4D Molecular Therapeutics Price Performance

The company has a debt-to-equity ratio of 0.05, a quick ratio of 8.03 and a current ratio of 8.03. The firm has a fifty day simple moving average of $11.61 and a two-hundred day simple moving average of $10.12. The firm has a market cap of $874.45 million, a PE ratio of -6.02 and a beta of 2.73.

4D Molecular Therapeutics (NASDAQ:FDMT) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.02) by ($0.02). 4D Molecular Therapeutics had a negative return on equity of 41.33% and a negative net margin of 194.74%.The firm had revenue of $3.78 million for the quarter, compared to analysts’ expectations of $3.62 million. Equities analysts predict that 4D Molecular Therapeutics, Inc. will post -4.09 EPS for the current fiscal year.

Insiders Place Their Bets

In other 4D Molecular Therapeutics news, insider Scott Bizily sold 9,810 shares of the stock in a transaction on Tuesday, June 23rd. The shares were sold at an average price of $12.00, for a total transaction of $117,720.00. Following the completion of the transaction, the insider owned 8,617 shares in the company, valued at $103,404. This trade represents a 53.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider David Kirn sold 12,415 shares of the stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $10.05, for a total transaction of $124,770.75. Following the transaction, the insider owned 871,737 shares of the company’s stock, valued at $8,760,956.85. This trade represents a 1.40% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 200,496 shares of company stock worth $2,240,244. 7.90% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in FDMT. Sei Investments Co. increased its stake in 4D Molecular Therapeutics by 8.9% during the first quarter. Sei Investments Co. now owns 12,862 shares of the company’s stock worth $120,000 after acquiring an additional 1,050 shares during the last quarter. Martingale Asset Management L P lifted its stake in shares of 4D Molecular Therapeutics by 12.4% in the 4th quarter. Martingale Asset Management L P now owns 11,775 shares of the company’s stock valued at $88,000 after purchasing an additional 1,303 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of 4D Molecular Therapeutics by 3.7% in the 3rd quarter. Dimensional Fund Advisors LP now owns 58,006 shares of the company’s stock valued at $504,000 after purchasing an additional 2,069 shares during the last quarter. Russell Investments Group Ltd. boosted its holdings in shares of 4D Molecular Therapeutics by 11.7% in the 2nd quarter. Russell Investments Group Ltd. now owns 21,816 shares of the company’s stock worth $81,000 after purchasing an additional 2,284 shares during the period. Finally, Prelude Capital Management LLC boosted its holdings in shares of 4D Molecular Therapeutics by 11.1% in the 3rd quarter. Prelude Capital Management LLC now owns 23,000 shares of the company’s stock worth $200,000 after purchasing an additional 2,300 shares during the period. Hedge funds and other institutional investors own 99.27% of the company’s stock.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.